Segment Data (Schedule of Net Sales from External Customers by Products) (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Jun. 24, 2016	Jun. 26, 2015	Jun. 24, 2016	Jun. 26, 2015
Segment Reporting Information [Line Items]
Net sales		$ 970.6	$ 877.3	$ 2,803.4	$ 2,464.5
Operating Segments
Segment Reporting Information [Line Items]
Net sales		956.7	862.9	2,762.7	2,429.2
Operating Segments | Specialty Brands
Segment Reporting Information [Line Items]
Net sales		589.3	446.2	1,667.5	1,154.1
Operating Segments | Specialty Generics
Segment Reporting Information [Line Items]
Net sales		263.4	307.9	785.4	954.9
Operating Segments | Nuclear Imaging
Segment Reporting Information [Line Items]
Net sales		104.0	108.8	309.8	320.2
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Net sales	[1]	13.9	14.4	40.7	35.3
H. P. Acthar Gel | Operating Segments | Specialty Brands
Segment Reporting Information [Line Items]
Net sales		298.3	268.7	833.4	763.1
Hemostasis Products | Operating Segments | Specialty Brands
Segment Reporting Information [Line Items]
Net sales		13.9	0.0	25.3	0.0
Ofirmev | Operating Segments | Specialty Brands
Segment Reporting Information [Line Items]
Net sales		70.7	62.1	208.7	201.6
Therakos | Operating Segments | Specialty Brands
Segment Reporting Information [Line Items]
Net sales		52.5	0.0	153.1	0.0
Inomax | Operating Segments | Specialty Brands
Segment Reporting Information [Line Items]
Net sales		121.1	81.5	347.4	81.5
Other | Operating Segments | Specialty Brands
Segment Reporting Information [Line Items]
Net sales		32.8	33.9	99.6	107.9
Other | Operating Segments | Specialty Generics
Segment Reporting Information [Line Items]
Net sales		45.6	51.5	135.9	162.4
Oxycodone (API) | Operating Segments | Specialty Generics
Segment Reporting Information [Line Items]
Net sales		30.6	31.6	97.4	127.2
Hydrocodone (API) | Operating Segments | Specialty Generics
Segment Reporting Information [Line Items]
Net sales		38.2	37.4	115.7	138.0
Methylphenidate ER (Specialty Generics) | Operating Segments | Specialty Generics
Segment Reporting Information [Line Items]
Net sales		24.3	30.0	80.1	112.6
Other Controlled Substances | Operating Segments | Specialty Generics
Segment Reporting Information [Line Items]
Net sales		$ 124.7	$ 157.4	$ 356.3	$ 414.7

[1] Represents historical CMDS-related intercompany transactions that represent Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.